{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:05:09Z","timestamp":1792443909799,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"am","delay-in-days":405,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.smim.2024.101884","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T23:46:57Z","timestamp":1718063217000},"page":"101884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Durability of immune responses to SARS-CoV-2 infection and vaccination"],"prefix":"10.1016","volume":"73","author":[{"given":"Mehul S.","family":"Suthar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10223","key":"10.1016\/j.smim.2024.101884_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.smim.2024.101884_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148517","article-title":"Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19","volume":"131","author":"Ahn","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2024.101884_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2020.109819","article-title":"Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy","volume":"188","author":"Jayaweera","year":"2020","journal-title":"Environ. Res"},{"issue":"5","key":"10.1016\/j.smim.2024.101884_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-CoV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat. Rev. Microbiol"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.molmed.2023.01.003","article-title":"Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines","volume":"29","author":"Fraser","year":"2023","journal-title":"Trends Mol. Med"},{"issue":"5","key":"10.1016\/j.smim.2024.101884_bib7","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","article-title":"Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer","volume":"15","author":"Tian","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41423-023-01104-y","article-title":"SARS-CoV-2 and innate immunity: the good, the bad, and the \"goldilocks","volume":"21","author":"Sievers","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3934\/microbiol.2023015","article-title":"SARS-CoV-2 infection and immune responses","volume":"9","author":"Harne","year":"2023","journal-title":"AIMS Microbiol"},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.smim.2024.101884_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.15585\/mmwr.mm7222a3","article-title":"Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status - United States, April 2021-September 2022","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"7923","key":"10.1016\/j.smim.2024.101884_bib13","first-page":"603","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1","volume":"608","author":"Wang","year":"2022","journal-title":"Ba. 4 Ba. 5, Nat."},{"issue":"7889","key":"10.1016\/j.smim.2024.101884_bib14","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-021-04188-6","article-title":"The emergence, genomic diversity and global spread of SARS-CoV-2","volume":"600","author":"Li","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib15","first-page":"2024","article-title":"Dispersion patterns of SARS-CoV-2 variants Gamma, Lambda and Mu in Latin America and the Caribbean","volume":"15","author":"Graf","year":"1837","journal-title":"Nat. Commun."},{"issue":"7854","key":"10.1016\/j.smim.2024.101884_bib16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101884_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.751778","article-title":"The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape","volume":"12","author":"Tian","year":"2021","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.smim.2024.101884_bib18","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1002\/jmv.27643","article-title":"The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant","volume":"94","author":"Tian","year":"2022","journal-title":"J. Med Virol."},{"issue":"11","key":"10.1016\/j.smim.2024.101884_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.smim.2024.101884_bib20","article-title":"Durability of immune responses to the booster mRNA vaccination against COVID-19","author":"Arunachalam","year":"2022","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"issue":"645","key":"10.1016\/j.smim.2024.101884_bib22","doi-asserted-by":"crossref","first-page":"eabn8543","DOI":"10.1126\/scitranslmed.abn8543","article-title":"SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies","volume":"14","author":"Lusvarghi","year":"2022","journal-title":"Sci. Transl. Med"},{"issue":"3","key":"10.1016\/j.smim.2024.101884_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat. Med"},{"issue":"16","key":"10.1016\/j.smim.2024.101884_bib24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"Yu","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"7906","key":"10.1016\/j.smim.2024.101884_bib25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.smim.2024.101884_bib26","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Rep. Med"},{"issue":"6529","key":"10.1016\/j.smim.2024.101884_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.21616","article-title":"Long-term immune response to SARS-CoV-2 infection among children and adults after mild infection","volume":"5","author":"Di Chiara","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib31","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep. Med"},{"issue":"5","key":"10.1016\/j.smim.2024.101884_bib32","doi-asserted-by":"crossref","first-page":"784 e1","DOI":"10.1016\/j.cmi.2021.01.005","article-title":"Centre for emerging viral, antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study","volume":"27","author":"L'Huillier","year":"2021","journal-title":"Clin. Microbiol Infect."},{"issue":"6","key":"10.1016\/j.smim.2024.101884_bib33","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s11684-020-0822-5","article-title":"Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection","volume":"14","author":"Tan","year":"2020","journal-title":"Front Med"},{"issue":"9","key":"10.1016\/j.smim.2024.101884_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102937","article-title":"Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms","volume":"24","author":"Carreno","year":"2021","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib35","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/cid\/ciab607","article-title":"Long-term persistence of spike protein antibody and predictive modeling of antibody dynamics after infection with severe acute respiratory syndrome coronavirus 2","volume":"74","author":"Grandjean","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.smim.2024.101884_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107967","article-title":"Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults","volume":"26","author":"Joshi","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41467-021-27595-9","article-title":"Robust and durable serological response following pediatric SARS-CoV-2 infection","volume":"13","author":"Renk","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.smim.2024.101884_bib38","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jama.2022.1206","article-title":"Durability of anti-spike antibodies in infants after maternal COVID-19 vaccination or natural infection","volume":"327","author":"Shook","year":"2022","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.smim.2024.101884_bib39","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1016\/j.cell.2023.08.044","article-title":"Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth","volume":"186","author":"Wimmers","year":"2023","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.smim.2024.101884_bib40","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1128\/JVI.06075-11","article-title":"Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans","volume":"86","author":"Wrammert","year":"2012","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J. Exp. Med."},{"issue":"7867","key":"10.1016\/j.smim.2024.101884_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"595","author":"Turner","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.smim.2024.101884_bib43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/eji.202048838","article-title":"Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia","volume":"50","author":"De Biasi","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib44","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2020.09.002","article-title":"Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2","volume":"28","author":"Nielsen","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"issue":"6638","key":"10.1016\/j.smim.2024.101884_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.smim.2024.101884_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib48","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.smim.2024.101884_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050433","article-title":"An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times","volume":"9","author":"Garcia-Montero","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.smim.2024.101884_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.smim.2024.101884_bib51","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"J.H. Beigel, R.N.A.S.G. m, safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad673","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine","volume":"11","author":"Babu","year":"2024","journal-title":"Open Forum Infect. Dis."},{"issue":"7830","key":"10.1016\/j.smim.2024.101884_bib53","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.smim.2024.101884_bib54","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"7830","key":"10.1016\/j.smim.2024.101884_bib55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.smim.2024.101884_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.smim.2024.101884_bib57","article-title":"Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study","volume":"6","author":"Bruxvoort","year":"2022","journal-title":"Lancet Reg. Health Am."},{"issue":"7904","key":"10.1016\/j.smim.2024.101884_bib58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of B cell response to mRNA vaccination","volume":"604","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101884_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104735","article-title":"SARS-CoV-2 specific plasma cells acquire long-lived phenotypes in human bone marrow","volume":"95","author":"Schulz","year":"2023","journal-title":"EBioMedicine"},{"issue":"7870","key":"10.1016\/j.smim.2024.101884_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.smim.2024.101884_bib61","doi-asserted-by":"crossref","first-page":"ofae051","DOI":"10.1093\/ofid\/ofae051","article-title":"Real-world effectiveness of mRNA COVID-19 vaccines among US nursing home residents aged >\/=65 years in the pre-delta and high delta periods","volume":"11","author":"Lu","year":"2024","journal-title":"Open Forum Infect. Dis."},{"issue":"24","key":"10.1016\/j.smim.2024.101884_bib62","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.smim.2024.101884_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11050985","article-title":"Real-World Effectiveness of Four Types of COVID-19 Vaccines","volume":"11","author":"Abdel-Qader","year":"2023","journal-title":"Vaccines"},{"issue":"23","key":"10.1016\/j.smim.2024.101884_bib64","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"R.N.A.S.G. m, Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.smim.2024.101884_bib65","doi-asserted-by":"crossref","unstructured":"M.S. Suthar, P.S. Arunachalam, M. Hu, N. Reis, M. Trisal, O. Raeber, S. Chinthrajah, M.E. Davis-Gardner, K. Manning, P. Mudvari, E. Boritz, S. Godbole, A.R. Henry, D.C. Douek, P. Halfmann, Y. Kawaoka, V.I. Zarnitsyna, K. Nadeau, B. Pulendran, Durability of immune responses to the BNT162b2 mRNA vaccine, (2021) 2021.09.30.462488.","DOI":"10.1101\/2021.09.30.462488"},{"issue":"11","key":"10.1016\/j.smim.2024.101884_bib66","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.4049\/jimmunol.2001420","article-title":"Evaluation of cellular and serological responses to acute SARS-CoV-2 infection demonstrates the functional importance of the receptor-binding domain","volume":"206","author":"Mantus","year":"2021","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2024.101884_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167955","article-title":"Durability of immune responses to mRNA booster vaccination against COVID-19","volume":"133","author":"Arunachalam","year":"2023","journal-title":"J. Clin. Invest"},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib69","volume":"3","author":"Lyke","year":"2022","journal-title":"Cell Rep. Med"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2335052","article-title":"Effectiveness and durability of mRNA-1273 BA.4\/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4\/BA.5 and XBB sublineages","volume":"20","author":"Ackerson","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29365","article-title":"Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster","volume":"96","author":"Favresse","year":"2024","journal-title":"J. Med Virol."},{"issue":"8","key":"10.1016\/j.smim.2024.101884_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj9945","article-title":"Waning immunity and IgG4 responses following bivalent mRNA boosting","volume":"10","author":"Lasrado","year":"2024","journal-title":"Sci. Adv."},{"issue":"14","key":"10.1016\/j.smim.2024.101884_bib73","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMc2209651","article-title":"Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection","volume":"387","author":"Havervall","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"577","key":"10.1016\/j.smim.2024.101884_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.smim.2024.101884_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00279-22","article-title":"Mucosal and systemic responses to severe acute respiratory syndrome coronavirus 2 vaccination determined by severity of primary infection","volume":"7","author":"Sajadi","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.smim.2024.101884_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104893","article-title":"SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses","volume":"98","author":"Puhach","year":"2023","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib77","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(22)00834-9","article-title":"7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection","volume":"23","author":"Marking","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2024.101884_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104402","article-title":"SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination","volume":"87","author":"Liew","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03931-3","article-title":"Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination","volume":"11","author":"Mades","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib80","article-title":"SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies","volume":"2","author":"Cao","year":"2023","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"10.1016\/j.smim.2024.101884_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744887","article-title":"The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines","volume":"12","author":"Chan","year":"2021","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.smim.2024.101884_bib82","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/cid\/ciac934","article-title":"Comparison of levels of nasal, salivary, and plasma antibody to severe acute respiratory syndrome coronavirus 2 during natural infection and after vaccination","volume":"76","author":"Cohen","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00102-7","article-title":"Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose","volume":"4","author":"Bladh","year":"2023","journal-title":"Lancet Microbe"},{"issue":"7833","key":"10.1016\/j.smim.2024.101884_bib84","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.smim.2024.101884_bib85","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib86","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"48","key":"10.1016\/j.smim.2024.101884_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci. Immunol."},{"issue":"76","key":"10.1016\/j.smim.2024.101884_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2024.101884_bib89","unstructured":"S.R. Elizaldi, Y.S. Lakshmanappa, J.W. Roh, B.A. Schmidt, T.D. Carroll, K.D. Weaver, J.C. Smith, J.D. Deere, J. Dutra, M. Stone, R.L. Sammak, K.J. Olstad, J.R. Reader, Z.M. Ma, N.K. Nguyen, J. Watanabe, J. Usachaenko, R. Immareddy, J.L. Yee, D. Weiskopf, A. Sette, D. Hartigan-O\u2032Connor, S.J. McSorley, J.H. Morrison, N.K. Tran, G. Simmons, M.P. Busch, P.A. Kozlowski, K.K.A. Van Rompay, C.J. Miller, S.S. Iyer, SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques, bioRxiv (2020)."},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib90","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s42003-022-04310-y","article-title":"The dynamics of gammadelta T cell responses in nonhuman primates during SARS-CoV-2 infection","volume":"5","author":"Fears","year":"2022","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib91","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1038\/s41467-023-42433-w","article-title":"Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination","volume":"14","author":"Mitsi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2024.101884_bib92","article-title":"IL-10 suppresses T cell expansion while promoting tissue-resident memory cell formation during SARS-CoV-2 infection in rhesus macaques","author":"Nelson","year":"2022","journal-title":"bioRxiv"},{"issue":"77","key":"10.1016\/j.smim.2024.101884_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq7647","article-title":"CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques","volume":"7","author":"Liu","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2024.101884_bib94","series-title":"bioRxiv","article-title":"CD4+ and CD8+ T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment","author":"Kar","year":"2024"},{"issue":"6512","key":"10.1016\/j.smim.2024.101884_bib95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib96","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/s41467-023-38020-8","article-title":"Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion","volume":"14","author":"Eser","year":"2023","journal-title":"Nat. Commun."},{"issue":"7896","key":"10.1016\/j.smim.2024.101884_bib97","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-021-04345-x","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults","volume":"602","author":"Yoshida","year":"2022","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.smim.2024.101884_bib98","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.cell.2021.07.023","article-title":"Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19","volume":"184","author":"Ziegler","year":"2021","journal-title":"Cell"},{"issue":"6572","key":"10.1016\/j.smim.2024.101884_bib99","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib100","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.immuni.2023.03.005","article-title":"Spheromers reveal robust T cell responses to the Pfizer\/BioNTech vaccine and attenuated peripheral CD8(+) T cell responses post SARS-CoV-2 infection","volume":"56","author":"Gao","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib101","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41590-023-01692-x","article-title":"Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8(+) T cells in persons with previous COVID-19","volume":"25","author":"Ford","year":"2024","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2024.101884_bib102","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"Lipsitch","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"7918","key":"10.1016\/j.smim.2024.101884_bib104","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-04830-x","article-title":"Omicron infection enhances Delta antibody immunity in vaccinated persons","volume":"607","author":"Khan","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.smim.2024.101884_bib105","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.cell.2022.03.019","article-title":"Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants","volume":"185","author":"Servellita","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib106","article-title":"Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination","volume":"3","author":"Mantus","year":"2022","journal-title":"Cell Rep. Med."},{"issue":"6561","key":"10.1016\/j.smim.2024.101884_bib107","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101884_bib108","doi-asserted-by":"crossref","first-page":"1241038","DOI":"10.3389\/fimmu.2023.1241038","article-title":"Cross-reactive humoral and CD4(+) T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population","volume":"14","author":"Martel","year":"2023","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib109","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.chom.2023.12.010","article-title":"Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant","volume":"32","author":"Muller","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.smim.2024.101884_bib110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.chom.2023.12.003","article-title":"Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant","volume":"32","author":"Nesamari","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.smim.2024.101884_bib111","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib112","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.immuni.2023.02.017","article-title":"SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses","volume":"56","author":"Koutsakos","year":"2023","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.smim.2024.101884_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108474","article-title":"Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity","volume":"26","author":"Lineburg","year":"2023","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib114","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02407-23","article-title":"SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients","volume":"15","author":"Chen","year":"2024","journal-title":"mBio"},{"issue":"91","key":"10.1016\/j.smim.2024.101884_bib115","doi-asserted-by":"crossref","first-page":"eade6132","DOI":"10.1126\/sciimmunol.ade6132","article-title":".2 breakthrough infection elicits CD8(+) T cell responses recognizing the spike of later Omicron subvariants","volume":"9","author":"Kim","year":"2024","journal-title":"Sci. Immunol."},{"issue":"7961","key":"10.1016\/j.smim.2024.101884_bib116","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-023-06025-4","article-title":"SARS-CoV-2 Omicron boosting induces de novo B cell response in humans","volume":"617","author":"Alsoussi","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.smim.2024.101884_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","author":"Hassan","year":"2021","journal-title":"Cell Rep."},{"issue":"7998","key":"10.1016\/j.smim.2024.101884_bib118","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-023-06951-3","article-title":"Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques","volume":"626","author":"McMahan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101884_bib119","article-title":"Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates","author":"Moliva","year":"2023","journal-title":"bioRxiv"},{"issue":"66","key":"10.1016\/j.smim.2024.101884_bib120","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj5129","article-title":"Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA","volume":"6","author":"Oh","year":"2021","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2024.101884_bib121","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41541-023-00662-6","article-title":"Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico","volume":"8","author":"Ponce-de-Leon","year":"2023","journal-title":"NPJ Vaccin."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532324000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532324000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T09:48:44Z","timestamp":1729072124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532324000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":121,"alternative-id":["S1044532324000228"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2024.101884","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durability of immune responses to SARS-CoV-2 infection and vaccination","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2024.101884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101884"}}